Amgen is developing a GLP-1/GIP dual agonist called MariTide (currently in phase 3 trials expected to complete in 2027), which is administered as a once-monthly injection
EPP is caused by enzyme deficiency, leading to a buildup of protoporphyrin IX in the skin and blood
It analyzes pathway-level variants (MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction
thus, optimising nutritional intake alongside pharmacological adjustments can be an effective strategy for symptom control [60, 92]
It's worth noting that if you experience vomiting or diarrhoea while taking Rybelsus and oral contraceptives, you should follow the usual missed-pill advice in your contraceptive leaflet
Research shows that a dose given during the day still improves sleep that night and potentially subsequent nights